Iseas, Soledad
Roca, Enrique L.
O’Connor, Juan M.
Eleta, Martin
Sanchez-Luceros, Analia
Di Leo, Daniela
Tinelli, Marcelo
Fara, Maria L.
Spitzer, Eduardo
Demarco, Ignacio A.
Ripoll, Giselle V.
Pifano, Marina
Garona, Juan
Alonso, Daniel F.
Funding for this research was provided by:
National Cancer Institute (INC 14-16)
Elea-Phoenix Laboratories (NA)
Chemo-Romikin (NA)
Article History
Received: 7 January 2020
Accepted: 14 February 2020
First Online: 12 March 2020
Compliance with ethical standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all participants included in the study.
: D. Di Leo, M. Tinelli, M.L. Fara and E. Spitzer are employees of Elea-Phoenix Laboratories. I.A. Demarco is employee of Chemo-Romikin. G.V. Ripoll, M. Pifano, J. Garona and D.F. Alonso have served in a consultant/advisory role for Elea-Phoenix Laboratories and Chemo-Romikin. G.V. Ripoll and D.F. Alonso are inventors in a patent related to the therapeutic use of vasopressin analogs, which belongs to their academic institution. All other authors have no conflicts of interests to declare.